AirSculpt Technologies, Inc. (AIRS)
NASDAQ: AIRS · Real-Time Price · USD
2.290
-0.200 (-8.03%)
At close: Mar 28, 2025, 4:00 PM
2.260
-0.030 (-1.31%)
After-hours: Mar 28, 2025, 7:49 PM EDT

Company Description

AirSculpt Technologies, Inc., together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States, Canada, and the United Kingdom.

The company offers AirSculpt, a body contouring treatment that removes fat and tightens skin while sculpting targeted areas of the body in a minimally invasive procedure.

It also provides AirSculpt+, a procedure that permanently removes fat and tightens the skin with unparalleled precision and finesse; and AirSculpt Smooth, an advanced cellulite removal tool.

In addition, it provides fat removal procedures across treatment areas, such as the stomach, back, and buttocks; and fat transfer procedures that transfers the patient’s own fat cells to enhance the buttocks, breasts, hips, aging hands, or other areas.

Further, the company’s body contouring procedures include the Power BBL, a Brazilian butt lift procedure; the Up a Cup, a breast enhancement procedure; and the Hip Flip, an hourglass contouring procedure.

Additionally, it operates various centers. AirSculpt Technologies, Inc. was founded in 2012 and is headquartered in Miami Beach, Florida.

AirSculpt Technologies, Inc.
AirSculpt Technologies logo
Country United States
Founded 2012
IPO Date Oct 29, 2021
Industry Medical Care Facilities
Sector Healthcare
Employees 422
CEO Yogesh Jashnani

Contact Details

Address:
1111 Lincoln Road, Suite 802
Miami Beach, Florida 33139
United States
Phone 786 709 9690
Website airsculpt.com

Stock Details

Ticker Symbol AIRS
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $11.00
CIK Code 0001870940
CUSIP Number 009496100
ISIN Number US0094961002
Employer ID 87-1471855
SIC Code 8011

Key Executives

Name Position
Yogesh Jashnani Chief Executive Officer and Director
Dr. Aaron J. Rollins M.D. Founder and Executive Chairman
Philip Bodie Chief Accounting Officer
Stephanie Evans Greene Chief Marketing Officer

Latest SEC Filings

Date Type Title
Mar 28, 2025 ARS Filing
Mar 28, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 28, 2025 DEF 14A Other definitive proxy statements
Mar 24, 2025 EFFECT Notice of Effectiveness
Mar 14, 2025 S-3 Registration statement under Securities Act of 1933
Mar 14, 2025 10-K Annual Report
Mar 14, 2025 8-K Current Report
Feb 7, 2025 SCHEDULE 13G/A Filing
Jan 13, 2025 8-K Current Report
Dec 26, 2024 8-K Current Report